US 10400239
Compositions and methods for inhibiting expression of the ALAS1 gene
granted A61KA61K31/713A61K47/60
Quick answer
US patent 10400239 (Compositions and methods for inhibiting expression of the ALAS1 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 51
- CPC classes
- A61K, A61K31/713, A61K47/60, A61K48/00, A61P